Financial Daily from THE HINDU group of publications
Thursday, Jun 13, 2002
Financial Daily from THE HINDU group of publications Thursday, Jun 13, 2002 |
|
|
|
|
|
Corporate
-
People Uday Saxena to oversee global R&D at Dr Reddy's Our Bureau
HYDERABAD, June 12 DR Reddy's Laboratories Ltd, the Hyderabad-based global pharma giant listed on the New York Stock Exchange (NYSE), has appointed Dr Uday Saxena as its Chief Scientific Officer (CSO). Dr Saxena was the President and Chief Executive Officer of Reddy US Therapeutics Inc, a US-based biopharmaceutical company and subsidiary of Dr Reddy's based in Atlanta. In his new capacity, Dr Saxena would oversee the global R&D activities of the company. Announcing this here on Wednesday, Dr Reddy's Executive Vice-Chairman and Chief Executive Officer, Mr G.V. Prasad, said: "Dr Saxena's appointment as CSO will enable us to create a distinctive global research organisation by integrating our research capabilities in India and the US.'' According to the company, Dr Saxena, who joined Dr Reddy's in early 2000 as head of Reddy US Therapeutics, was instrumental in building a top-notch team of scientists and in setting up a discovery programme focussed on novel therapeutics that address unmet medical needs in diabetes, inflammation and cardiovascular disease. Under the initiative of Dr Saxena with an experience of over a decade in the pharmaceutical and biotech industries, Reddy US Therapeutics had validated three new drug targets in cell proliferation, diabetic vasculopathy and inflammation. In cell proliferation, the company now has a lead compound for treating restenosis, which has successfully completed proof-of-concept in the animal model, the release said.
Send this article to Friends by E-Mail
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2002, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|